Abstract：Objective: To investigate the effect on the changes of lung microbial in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) with respiratory failure. Methods: 182 patients with acute exacerbation of COPD with respiratory failure from our hospital were selected. The sputum specimens were inoculated on blood plate, Jimmy Kang Kai, flat plate and flat sandy Paull chocolate. The drug resistance and changes of lung microbial continuity were tested and compared. Results: Gram-negative bacteria were the main bacteria, Gram-positive bacteria and fungi were more, and the proportion of microorganisms was gradually increasing (P<0.05). The resistance rate of tetracycline in Pseudomonas aeruginosa showed a downward trend (P<0.05). The drug resistance rate of amikanamycin, carbapenems, levofloxacin, piperacillin tazobactam and cefoperazone sulbactam increased (P<0.05). The resistance rates of the treatment of Bauman 's Acinetobacter to common antibiotics, carbon - and - resistant strains, and the resistance rates of the drug to the south of the Bacillus were higher,(P<0.05). The resistance rate of Klebsiella pneumoniae to gentamicin, carbapenem, beta lactamase inhibitor and three generation cephalosporins increased (P<0.05). There was a downward trend in piperacillin tazobactam (P<0.05). Escherichia coli was the most common drug resistance rate was on the rise,(P<0.05). The resistance rate of the drug in the south of the drug and the resistance of the ammonia to the south of the ammonia was decreased(P<0.05). Staphylococcus aureus s a rising trend in the use of antibiotics and most of the drug resistance rate,(P<0.05). Clindamycin resistance and SMZ-TMP rate decreased(P<0.05). Conclusion: The continuous changes in lung microbes in patients with acute exacerbation of COPD and respiratory failure have diagnostic significance for the development of acute exacerbation of COPD, the development of respiratory failure and the treatment of respiratory failure.
刘荣, 耿新普, 邵星星. 慢性阻塞性肺病急性恶化合并呼吸衰竭患者肺部微生物变化研究[J]. 河北医学, 2018, 24(9): 1454-1458.
LIU Rong, GENG Xinpu, SHAO Xingxing. The Changes of Lung Microbial in Patients with Acute Exacerbation of COPD with Respiratory Failure. HeBei Med, 2018, 24(9): 1454-1458.
[1] Vestbo J, Hurd S S, Agusti A G, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary[J]. American journal of respiratory and critical care medicine, 2013, 187(4): 347~365. [2] Lange P, Celli B, Agustí A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease[J]. New England Journal of Medicine, 2015, 373(2): 111~122. [3] Qaseem A, Wilt T J, Weinberger S E, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society[J]. Annals of internal medicine, 2011, 155(3): 179~191. [4] Leuppi J D, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial[J]. Jama, 2013, 309(21): 2223~2231. [5] Celli B R, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease[J]. American journal of respiratory and critical care medicine, 2012, 185(10): 1065~1072. [6] Lange P, Marott J L, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population[J]. American journal of respiratory and critical care medicine, 2012, 186(10): 975~981. [7] Polkey M I, Spruit M A, Edwards L D, et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization[J]. American journal of respiratory and critical care medicine, 2013, 187(4): 382~386. [8] McDonough J E, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease[J]. New England Journal of Medicine, 2011, 365(17): 1567~1575. [9] Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality[J]. Thorax, 2012, 67(11): 957~963. [10] Vanfleteren L E G W, Spruit M A, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease[J]. American journal of respiratory and critical care medicine, 2013, 187(7): 728~735. [11] Barnes P J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease[J]. Journal of Allergy and Clinical Immunology, 2013, 131(3): 636~645. [12] Tuder R M, Petrache I. Pathogenesis of chronic obstructive pulmonary disease[J]. The Journal of clinical investigation, 2012, 122(8): 2749. [13] Sze M A, Dimitriu P A, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease[J]. American journal of respiratory and critical care medicine, 2012, 185(10): 1073~1080. [14] Thomsen M, Ingebrigtsen T S, Marott J L, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease[J]. Jama, 2013, 309(22): 2353~2361. [15] Mackay A J, Donaldson G C, Patel A R C, et al. Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations[J]. American journal of respiratory and critical care medicine, 2012, 185(11): 1218~1224.
2018, Vol. 24 
冀公网安备13080202000677号